Bay Area biotech hauls in $62M to pay the freight on early-stage CD33/CD3 T cell engager

Retrieved on: 2019-09-23 22:26:49

Tags for this article:

Click the tags to see associated articles and topics

Bay Area biotech hauls in $62M to pay the freight on early-stage CD33/CD3 T cell engager. View article details on hiswai:

Excerpt

<div>NanoDimension and <b>Qiming Venture Partners</b> USA led the round, bulking up on a big syndicate that includes new investors Clough Capital, Aju IB, ...</div>

Article found on:

View Original Article